Ingenix Raises $14.2M in Seed-Extension Round Led by Sofinnova Partners
Warsaw-based AI biology company Ingenix announced a €13 million ($14.2 million) seed‑extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC. The funding will be used to scale its Biological Reasoning Engine and broaden access to pharma and biotech partners. The round follows a €9 million seed round in April 2025.
Poolbeg Pharma: What US Payers Really Said
The interview with Acumentis partner Chris Grimes‑Crompton examined US payer attitudes toward Poolbeg Pharma’s lead CAR‑T immunotherapy, PLB‑001, which aims to mitigate cytokine‑release syndrome (CRS) and enable broader use. Payers across commercial insurers, Medicare and Medicaid expressed strong receptivity. They indicated...
AI and the Future of Pharma with Bob Bradway, CEO of Amgen
Bob Bradway, Amgen’s long‑time CEO, discussed how the company has woven artificial intelligence into every stage of drug development, from early target discovery to commercial launch. Amgen’s first AI‑focused move was the 2012 acquisition of Decode, a Icelandic genetics...
Stanford Study Finds Existing Drug Reverses Muscle Loss From GLP‑1 Weight‑Loss Therapies
Stanford Medicine scientists demonstrated that a prostaglandin‑dehydrogenase inhibitor (PGDHi), already in trials for age‑related sarcopenia, prevents muscle loss and restores strength in mice treated with semaglutide, the GLP‑1 drug behind Ozempic and Wegovy. The pre‑clinical data could pave the way...
Legend Biotech Shares Surge 42% on Positive Phase 1 Data for LB2501 Lymphoma Therapy
Legend Biotech Corp. announced encouraging preliminary Phase 1 results for its LB2501 therapy in B‑cell non‑Hodgkin lymphoma, driving a 42% jump in its stock. The investigational CAR‑T candidate showed activity in 12 patients across two dose levels, highlighting a potential...
Rallybio to Acquire Avenzo in $215 Million Private‑Placement‑Backed Merger
Rallybio Corp. announced a definitive agreement to acquire Avenzo Therapeutics, creating a combined entity that will trade as Avenzo Therapeutics (AVZO). The deal is paired with an oversubscribed $215 million private placement, funding operations into late 2028 and leaving pre‑Rallybio shareholders...
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
On June 3, 2026 the FDA’s Center for Biologics Evaluation and Research issued a draft guidance allowing sponsors of somatic genome‑editing gene therapies to leverage existing CMC, nonclinical and clinical data in regulatory submissions. Sponsors must provide a product‑specific scientific rationale and...
Legend Biotech's LB2501 Shows Promise in Phase 1 Lymphoma Trial, Shares Surge 42%
Legend Biotech announced encouraging preliminary results from its LB2501 CD19/CD20 dual‑targeting CAR‑T trial in B‑cell non‑Hodgkin lymphoma, lifting the stock more than 42%. The data, from 12 patients across two dose levels, suggest a manufacturing‑free, single‑infusion therapy that could reshape...
Legend Surges on Early Data for ‘in Vivo’ Lymphoma Cell Therapy
Legend Biotech reported that its in‑vivo CAR‑T candidate LB2501 induced remission in all six patients receiving the higher dose in a first‑in‑human trial of relapsed lymphoma, with five complete responses. The therapy uses a viral vector to program immune cells...
Landmark Pancreatic Cancer Treatment Paves Way for Targeting Other Tricky Tumors
Revolution Medicines’ pan‑RAS inhibitor daraxonrasib more than doubled median overall survival in a phase III trial of 500 patients with advanced pancreatic cancer, extending life from 6.7 to 13.2 months. The drug uniquely disables all three RAS isoforms, overcoming a decades‑long...
Jared Kelly on Immune Priming & Survival Outcomes: Oncolytics Biotech’s Vision for Pelareorep
Oncolytics Biotech CEO Jared Kelly says the oncolytic virus pelareorep is evolving from a standalone candidate to an immune‑priming backbone that can boost checkpoint inhibitors, chemotherapy and other oncology combos. The company reports encouraging survival data, including a median overall...
WashU Engineers Hookworms to Produce Therapeutic Antibody Against Deadly Toxin
Researchers at Washington University School of Medicine have genetically altered human hookworms to produce an antibody that neutralizes tetrodotoxin, demonstrating a proof‑of‑concept for living drug factories inside the gut. The study, published in Nature Communications, could reshape treatment for chronic...
Novo Nordisk Introduces Wegovy Oral Weight‑Loss Pill in UAE, First Market Outside the U.S.
Novo Nordisk has launched the Wegovy oral weight‑loss pill in the United Arab Emirates, becoming the first country outside the United States to offer the GLP‑1 therapy. The approval follows the OASIS 4 trial, which showed an average 17% weight loss...
Johnson & Johnson's FcRn Blocker Nipocalimab Cuts Lupus Activity and Shows Promise in Sjögren’s
Johnson & Johnson announced that its FcRn blocker nipocalimab met the primary endpoint in the Phase 2 JASMINE study for systemic lupus erythematosus, delivering a 53.5% SRI‑4 response versus 46.7% for placebo. The company also presented exploratory biomarker data from...
ETH Zurich Bio‑Hybrid Microrobots Restore Nerve Function in Spinal‑Injured Animals
Researchers at ETH Zurich and the University of Zurich have built magnetoelectric nano‑powered microrobots that guide stem cells to damaged spinal cords. In zebrafish, the bots restored near‑normal swimming in three days; in mice, nerve fibers reconnected after 28 days,...
Zenas Biopharma's Obexelimab Hits Primary Endpoints in Phase 3 INDIGO Trial
Zenas Biopharma reported that its Phase 3 INDIGO trial of obexelimab met its primary and all key secondary endpoints in patients with Immunoglobulin G4‑Related Disease. The data were unveiled at the EULAR 2026 Congress in London and published in the...
In Animal Study, Nanobots Repair Spinal Cords
Researchers have combined induced pluripotent stem cells with magnetic nanobots (NPC‑bots) to target spinal‑cord injuries in zebrafish and mice. The nanobots are steered by external magnetic fields, delivering electrical stimulation that drives stem‑cell migration, differentiation, and integration. In zebrafish, the...
Celcuity Reports the P-III (VIKTORIA-1) Trial Data on Gedatolisib Combination for HR+/HER2- PIK3CA Mutant Advanced Breast Cancer
Celcuity presented Phase III VIKTORIA‑1 results showing that gedatolisib combined with fulvestrant, with or without palbociclib, markedly outperformed standard of care in HR+/HER2‑negative advanced breast cancer patients harboring PIK3CA mutations. The triplet regimen achieved a median progression‑free survival (mPFS) of 11.1 months...